Thomas Wobrock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Wobrock has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Peter Falkai
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany
13 shared publications - Wolfgang Gaebel
Department of Psychiatry and Psychotherapy, Heinrich-Heine University, Dusseldorf, Germany
7 shared publications - Alkomiet Hasan
Klinikum der Universität München
4 shared publications B. Janssen
Klinik und Poliklinik für Psychiatrie und Psychotherapie, LVR-Klinikum Düsseldorf, Heinrich-Heine-Universität, Medizinische Fakultät, Düsseldorf
4 shared publications- Berthold Langguth
Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany
3 shared publications - Christian Schmidt-Kraepelin
Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
3 shared publications
Latest Publications
- Open Access
- 21 December 2021
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (6) , 957-969
Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia
Background: Significant evidence links white matter (WM) microstructural abnormalities to cognitive impairment in schizophrenia (SZ), but the relationship of these abnormalities with functional outcome remains unclear. Methods: In two independent cohorts (C1, C2), patients with SZ were divided into two subgroups: patients with higher cognitive performance (SZ-HCP-C1, n = 25; SZ-HCP-C2, n = 24) and patients with lower cognitive performance (SZ-LCP-C1, n = 25; SZ-LCP-C2, n = 24). Healthy controls (HC) were included in both cohorts (HC-C1, n = 52; HC-C2, n = 27). We compared fractional anisotropy (FA) of the whole-brain WM skeleton between the three groups (SZ-LCP, SZ-HCP, HC) by a whole-brain exploratory approach and an atlas-defined WM regions-of-interest approach via tract-based spatial statistics. In addition, we explored whether FA values were associated with Global Assessment of Functioning (GAF) scores in the SZ groups. Results: In both cohorts, mean FA values of whole-brain WM skeleton were significantly lower in the SCZ-LCP group than in the SCZ-HCP group. Whereas in C1 the FA of the frontal part of the left inferior fronto-occipital fasciculus (IFOF) was positively correlated with GAF score, in C2 the FA of the temporal part of the left IFOF was positively correlated with GAF score. Conclusions: We provide robust evidence for WM microstructural abnormalities in SZ. These abnormalities are more prominent in patients with low cognitive performance and are associated with the level of functioning.
- 21 December 2021
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (6) , 957-969
Open AccessCognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia
Background: Significant evidence links white matter (WM) microstructural abnormalities to cognitive impairment in schizophrenia (SZ), but the relationship of these abnormalities with functional outcome remains unclear. Methods: In two independent cohorts (C1, C2), patients with SZ were divided into two subgroups: patients with higher cognitive performance (SZ-HCP-C1, n = 25; SZ-HCP-C2, n = 24) and patients with lower cognitive performance (SZ-LCP-C1, n = 25; SZ-LCP-C2, n = 24). Healthy controls (HC) were included in both cohorts (HC-C1, n = 52; HC-C2, n = 27). We compared fractional anisotropy (FA) of the whole-brain WM skeleton between the three groups (SZ-LCP, SZ-HCP, HC) by a whole-brain exploratory approach and an atlas-defined WM regions-of-interest approach via tract-based spatial statistics. In addition, we explored whether FA values were associated with Global Assessment of Functioning (GAF) scores in the SZ groups. Results: In both cohorts, mean FA values of whole-brain WM skeleton were significantly lower in the SCZ-LCP group than in the SCZ-HCP group. Whereas in C1 the FA of the frontal part of the left inferior fronto-occipital fasciculus (IFOF) was positively correlated with GAF score, in C2 the FA of the temporal part of the left IFOF was positively correlated with GAF score. Conclusions: We provide robust evidence for WM microstructural abnormalities in SZ. These abnormalities are more prominent in patients with low cognitive performance and are associated with the level of functioning.
- 1 February 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 192, 481-484
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia
- 1 February 2018
- Published by Elsevier in Schizophrenia Research
- Vol. 192, 481-484
Letter to the Editor: Influence of rTMS on smoking in patients with schizophrenia
- 1 March 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 181, 38-42
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
- 1 March 2017
- Published by Elsevier in Schizophrenia Research
- Vol. 181, 38-42
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
- 1 July 2016
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 13 (03) , 145-151
Brain stimulation methods for patients with schizophrenia – new therapies on the horizon?
Summary: Background: Non-invasive brain stimulation (NIBS) techniques offer new promising treatment options in schizophrenia. However, the evidence from meta-analyses and randomized clinical studies is limited. Results: For repetitive transcranial magnetic stimulation (rTMS) the clinical efficacy is highest for the 1-Hz rTMS over the left temporal cortex to improve auditory hallucinations, nevertheless there are studies showing no benefit. For negative symptoms rTMS could be offered keeping in mind the good tolerability. Transcranial direct current stimulation (tDCS) has a good risk-benefit ratio, but the evidence for schizophrenia symptoms is still derived from small sample studies. Electroconvulsive therapy (ECT) is the treatment option with the highest clinical efficacy for treatment-resistant schizophrenia, catatonia or other defined treatment circumstances, but has more adverse side effects. More research is needed to understand which stimulation technique could be recommended for a certain patient.
- 1 July 2016
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 13 (03) , 145-151
Brain stimulation methods for patients with schizophrenia – new therapies on the horizon?
Summary: Background: Non-invasive brain stimulation (NIBS) techniques offer new promising treatment options in schizophrenia. However, the evidence from meta-analyses and randomized clinical studies is limited. Results: For repetitive transcranial magnetic stimulation (rTMS) the clinical efficacy is highest for the 1-Hz rTMS over the left temporal cortex to improve auditory hallucinations, nevertheless there are studies showing no benefit. For negative symptoms rTMS could be offered keeping in mind the good tolerability. Transcranial direct current stimulation (tDCS) has a good risk-benefit ratio, but the evidence for schizophrenia symptoms is still derived from small sample studies. Electroconvulsive therapy (ECT) is the treatment option with the highest clinical efficacy for treatment-resistant schizophrenia, catatonia or other defined treatment circumstances, but has more adverse side effects. More research is needed to understand which stimulation technique could be recommended for a certain patient.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 12 (01) , 19-27
Die Aktualisierung der DGPPN S3-Leitlinie Schizophrenie - aktueller Stand
Zusammenfassung: Ausgangslage: Es gibt seit 2006 in Deutschland eine Leitlinie für die Behandlung der Schizophrenie auf dem S3-Niveau der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Fragestellung: Die im Jahre 2006 von der Deutschen Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) publizierte S3-Leitlinie Schizophrenie befindet sich derzeit in einem umfangreichen Revisionsprozess. Die Notwendigkeit der Aktualisierung ergibt sich daraus, dass seit 2006 eine Vielzahl neuer klinischer Studien durchgeführt und publiziert worden sind, die eine neue Bewertung der Evidenzen für viele Bereiche erfordern. Daneben wurden viele methodisch hochwertige Meta-Analysen publiziert, die in verschiedenen Bereichen der Therapie eine Anpassung der Evidenzbewertung gebieten. Ziele: Es stehen zunehmend Fragen nach einer verbesserten Funktionsfähigkeit im Alltag, dem subjektiven Wohlbefinden und der Lebensqualität im Fokus der klinischen Praxis. Diese sehr relevanten klinischen Endpunkte sind in der letzten Version der S3-Leitlinie zwar erwähnt worden, besaßen aber noch nicht die heute gesellschaftlich und im Fach geforderte Relevanz.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 12 (01) , 19-27
Die Aktualisierung der DGPPN S3-Leitlinie Schizophrenie - aktueller Stand
Zusammenfassung: Ausgangslage: Es gibt seit 2006 in Deutschland eine Leitlinie für die Behandlung der Schizophrenie auf dem S3-Niveau der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Fragestellung: Die im Jahre 2006 von der Deutschen Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) publizierte S3-Leitlinie Schizophrenie befindet sich derzeit in einem umfangreichen Revisionsprozess. Die Notwendigkeit der Aktualisierung ergibt sich daraus, dass seit 2006 eine Vielzahl neuer klinischer Studien durchgeführt und publiziert worden sind, die eine neue Bewertung der Evidenzen für viele Bereiche erfordern. Daneben wurden viele methodisch hochwertige Meta-Analysen publiziert, die in verschiedenen Bereichen der Therapie eine Anpassung der Evidenzbewertung gebieten. Ziele: Es stehen zunehmend Fragen nach einer verbesserten Funktionsfähigkeit im Alltag, dem subjektiven Wohlbefinden und der Lebensqualität im Fokus der klinischen Praxis. Diese sehr relevanten klinischen Endpunkte sind in der letzten Version der S3-Leitlinie zwar erwähnt worden, besaßen aber noch nicht die heute gesellschaftlich und im Fach geforderte Relevanz.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 34 (12) , 965-975
rTMS in der Therapie psychiatrischer Erkrankungen
Als transkranielle Magnetstimulation (TMS) wird ein Verfahren bezeichnet, bei dem ein Stimulator über eine Spule kurze elektromagnetische Pulse mit einer Flussdichte von bis zu 2 Tesla induziert, welche die Schädelkalotte mit wenig Abschwächung durchdringen und zu einer Depolarisierung neuronaler Zellverbände führen. Die Stromdichte am Stimulationsort wird von einer Vielzahl physikalischer und biologischer Parametern bestimmt: Spulengeometrie sowie -positionierung, der Abstand der Spule zum Kortex, die Pulsform, die Intensität, Frequenz und das Muster der Stimulation sowie die dreidimensionale Orientierung der stimulierten neuronalen Strukturen im Verhältnis zur Geometrie des Magnetfeldes. Bei der repetitiven transkraniellen Magnetstimulation (rTMS) werden mehrere elektromagnetische Einzelstimuli als Reizserien mit konstanter Wiederholungsrate appliziert. Mithilfe dieser repetitiven TMS können Veränderungen der neuronalen Aktivität induziert werden, die über die eigentliche Stimulationsdauer hinweg andauern. Im vorliegenden Themenheft wird die Datenlage zu etablierten und potenziellen therapeutischen Anwendungen der repetitiven transkraniellen Magnetstimulation in psychiatrischen Indikationsgebieten zusammengefasst. Eine Empfehlung mit Evidenzgrad A kann für die hochfrequente rTMS-Behandlung des linken dorsolateralen präfrontalen Kortex (DLPFC) bei depressiven Störungen ausgesprochen werden. Empfehlungen mit dem Evidenzgrad B bestehen für niederfrequente rTMS des rechten DLPFC bei der Behandlung depressiver Störungen und für hochfrequente rTMS des linken DLPFC bei depressiver Symptomatik von Patienten mit Parkinson-Syndrom. Wahrscheinlich besteht ein additiver Effekt von rTMS des DLPFC zu einer antidepressiven Pharmakotherapie. Eine Empfehlung mit dem Evidenzgrad C kann folgenden rTMS-Paradigmen zugesprochen werden: hochfrequente rTMS des linken DLPFC bei Patienten mit schizophrener Negativsymptomatik (trotz einer großen negativen Multicenterstudie), niederfrequente rTMS des linken TPC bei chronischem Tinnitus und akustischen Halluzinationen (trotz vieler Publikationen eher niedriges Evidenzniveau), hochfrequente rTMS des rechten DLPFC bei Patienten mit posttraumatischer Belastungsstörung und hochfrequente rTMS des linken DLPFC bei Nikotinabhängigkeit. Gerade bei der Behandlung von Patienten mit chronischem und therapieresistentem Erkrankungsverlauf ist zu erwarten, dass dem gesamten Bereich neurostimulatorischer Methoden eine steigende Bedeutung zukommen wird. Es bleibt zu hoffen, dass vor dem Hintergrund innovativer technischer Entwicklungen und verbesserter Studienmethodologie die transkranielle Magnetstimulation in der nahen Zukunft ihr volles therapeutisches Potenzial entfalten wird. Transcranial magnetic stimulation (TMS) is a neuromodulatory technique consisting of short electromagnetic stimuli of approx. 2 Tesla produced by a stimulator connected to a coil. These magnetic fields penetrate the skull painlessly resulting in a depolarization of cortical neurons. The power of the magnetic field at the target area is mainly determined by a variety of physical and biological parameters such as coil geometry, coil position, coil distance to cortical target, pulse form, stimulation intensity, frequency, stimulation pattern, threedimensional orientation of cortical target in relation to the geometry of the applied magnetic field. Repetitive transcranial magnetic stimulation (rTMS) means the serial application of several electromagnetic stimuli at a given repetition rate. rTMS is able to evoke lasting changes in neuronal activity by induction of neuroplastic activity. The aim of the presented special issue is to provide a comprehensive overview regarding established and potential therapeutic applications of rTMS in the treatment of psychiatric disorders. A level-A-recommendation (“definitively effective”) is obtained for high-frequency stimulation of the left dorsolateral prefrontal cortex (DLPFC) in depressive disorders. Level-B-evidence (“probably effective”) is available for: (i) low-frequency rTMS of the right DLPFC in depressive disorders and (ii) high-frequency rTMS of the left DLPFC in case of depressive symptoms in patients suffering from Parkinson’s disease (probably additive effect of rTMS to antidepressant medication). Level-C-evidence (“possibly effective”) is available for: high-frequency rTMS of the left DLPFC in the treatment of negative symptoms in schizophrenic patients (despite a large multicenter- trial with negative findings), low-frequency rTMS of the left temporoparietal cortex in chronic tinnitus and acoustic halluzinations (low level of evidence despite a large number of publications), high-frequency stimulation of the right DLPFC in posttraumatic stress disorder (PTSD), and high-frequency rTMS of the left DLPFC in nicotine craving. It is very likely that – especially in the treatment of patients with chronic and treatment resistant conditions – the whole spectrum of neuromodulatory treatments will obtain increasing importance in the future. Innovative technical advances and improved study methodology may increase the potential of repetitive transcranial magnetic stimulation as an innovative and noninvasive treatment approach. * Dieses Manuskript wurde als Positionspapier der Deutschen Gesellschaft für Hirnstimulation in der Psychiatrie (DGHP) erarbeitet.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 34 (12) , 965-975
rTMS in der Therapie psychiatrischer Erkrankungen
Als transkranielle Magnetstimulation (TMS) wird ein Verfahren bezeichnet, bei dem ein Stimulator über eine Spule kurze elektromagnetische Pulse mit einer Flussdichte von bis zu 2 Tesla induziert, welche die Schädelkalotte mit wenig Abschwächung durchdringen und zu einer Depolarisierung neuronaler Zellverbände führen. Die Stromdichte am Stimulationsort wird von einer Vielzahl physikalischer und biologischer Parametern bestimmt: Spulengeometrie sowie -positionierung, der Abstand der Spule zum Kortex, die Pulsform, die Intensität, Frequenz und das Muster der Stimulation sowie die dreidimensionale Orientierung der stimulierten neuronalen Strukturen im Verhältnis zur Geometrie des Magnetfeldes. Bei der repetitiven transkraniellen Magnetstimulation (rTMS) werden mehrere elektromagnetische Einzelstimuli als Reizserien mit konstanter Wiederholungsrate appliziert. Mithilfe dieser repetitiven TMS können Veränderungen der neuronalen Aktivität induziert werden, die über die eigentliche Stimulationsdauer hinweg andauern. Im vorliegenden Themenheft wird die Datenlage zu etablierten und potenziellen therapeutischen Anwendungen der repetitiven transkraniellen Magnetstimulation in psychiatrischen Indikationsgebieten zusammengefasst. Eine Empfehlung mit Evidenzgrad A kann für die hochfrequente rTMS-Behandlung des linken dorsolateralen präfrontalen Kortex (DLPFC) bei depressiven Störungen ausgesprochen werden. Empfehlungen mit dem Evidenzgrad B bestehen für niederfrequente rTMS des rechten DLPFC bei der Behandlung depressiver Störungen und für hochfrequente rTMS des linken DLPFC bei depressiver Symptomatik von Patienten mit Parkinson-Syndrom. Wahrscheinlich besteht ein additiver Effekt von rTMS des DLPFC zu einer antidepressiven Pharmakotherapie. Eine Empfehlung mit dem Evidenzgrad C kann folgenden rTMS-Paradigmen zugesprochen werden: hochfrequente rTMS des linken DLPFC bei Patienten mit schizophrener Negativsymptomatik (trotz einer großen negativen Multicenterstudie), niederfrequente rTMS des linken TPC bei chronischem Tinnitus und akustischen Halluzinationen (trotz vieler Publikationen eher niedriges Evidenzniveau), hochfrequente rTMS des rechten DLPFC bei Patienten mit posttraumatischer Belastungsstörung und hochfrequente rTMS des linken DLPFC bei Nikotinabhängigkeit. Gerade bei der Behandlung von Patienten mit chronischem und therapieresistentem Erkrankungsverlauf ist zu erwarten, dass dem gesamten Bereich neurostimulatorischer Methoden eine steigende Bedeutung zukommen wird. Es bleibt zu hoffen, dass vor dem Hintergrund innovativer technischer Entwicklungen und verbesserter Studienmethodologie die transkranielle Magnetstimulation in der nahen Zukunft ihr volles therapeutisches Potenzial entfalten wird. Transcranial magnetic stimulation (TMS) is a neuromodulatory technique consisting of short electromagnetic stimuli of approx. 2 Tesla produced by a stimulator connected to a coil. These magnetic fields penetrate the skull painlessly resulting in a depolarization of cortical neurons. The power of the magnetic field at the target area is mainly determined by a variety of physical and biological parameters such as coil geometry, coil position, coil distance to cortical target, pulse form, stimulation intensity, frequency, stimulation pattern, threedimensional orientation of cortical target in relation to the geometry of the applied magnetic field. Repetitive transcranial magnetic stimulation (rTMS) means the serial application of several electromagnetic stimuli at a given repetition rate. rTMS is able to evoke lasting changes in neuronal activity by induction of neuroplastic activity. The aim of the presented special issue is to provide a comprehensive overview regarding established and potential therapeutic applications of rTMS in the treatment of psychiatric disorders. A level-A-recommendation (“definitively effective”) is obtained for high-frequency stimulation of the left dorsolateral prefrontal cortex (DLPFC) in depressive disorders. Level-B-evidence (“probably effective”) is available for: (i) low-frequency rTMS of the right DLPFC in depressive disorders and (ii) high-frequency rTMS of the left DLPFC in case of depressive symptoms in patients suffering from Parkinson’s disease (probably additive effect of rTMS to antidepressant medication). Level-C-evidence (“possibly effective”) is available for: high-frequency rTMS of the left DLPFC in the treatment of negative symptoms in schizophrenic patients (despite a large multicenter- trial with negative findings), low-frequency rTMS of the left temporoparietal cortex in chronic tinnitus and acoustic halluzinations (low level of evidence despite a large number of publications), high-frequency stimulation of the right DLPFC in posttraumatic stress disorder (PTSD), and high-frequency rTMS of the left DLPFC in nicotine craving. It is very likely that – especially in the treatment of patients with chronic and treatment resistant conditions – the whole spectrum of neuromodulatory treatments will obtain increasing importance in the future. Innovative technical advances and improved study methodology may increase the potential of repetitive transcranial magnetic stimulation as an innovative and noninvasive treatment approach. * Dieses Manuskript wurde als Positionspapier der Deutschen Gesellschaft für Hirnstimulation in der Psychiatrie (DGHP) erarbeitet.
- 12 March 2014
- Published by Georg Thieme Verlag KG in Klinische Neurophysiologie
- Vol. 45 (01) , P102
Impact of brain-derived neurotrophic factor (BDNF) gene polymorphism on cortical inhibition in schizophrenia
Introduction: Neuronal plasticity is a characteristic feature of the human central nervous system to dynamically respond to changes and demands inducing synaptical and neurochemical alterations. Using transcranial magnetic stimulation (TMS) in an intermittent theta-burst stimulation (iTBS) protocol, impaired cortical plasticity has been reported to be associated with a val/met gene-polymorphism in the brain-derived neurotrophic factor (BDNF) gene. Based on neuropathological findings and neuroimaging studies, impaired cortical plasticity has been described as a common, yet not fully understood phenomenon in patients with schizophrenia. Objectives: The aim of the present study was to investigate the impact of the val/met BDNF gene-polymorphism on cortical plasticity in patients with schizophrenia. Materials & Methods: Cortical plasticity was investigated using anodal and cathodal transcranial direct current stimulation (tDCS) applied to the primary motor cortex, thus inducing long-term potentiation (LTP) and long-term depression (LTD), respectively. LTP and LTD effects were probed by single and paired pulse TMS protocols before and after tDCS stimulation in a cross-sectional sample of schizophrenia patients (SZ) and healthy controls (HC). TMS in all participants was conducted using a standard 70 mm-TMS figure-of-eight magnetic coil connected to a MagPro X 100 magnetic stimulator. Analyses were focused on resting-motor threshold (RMT), 1mV motor-evoked potential (MEP), short-interval intracortical inhibition (SICI at 3 ms), intracortical facilitation (ICF at 12 ms) and cortical silent period (CSP at 120% RMT). Results: The statistical analyses included n = 43 SZ and n = 44 HC participants (all numbers presented under reserve of further examination) thus resulting in the largest available sample to probe cortical plasticity parameters in BDNF-genotyped schizophrenia patients. Further results will be presented at the conference. Conclusion: The findings will give new insights into the influence of plasticity-associated gene polymorphisms and the pathophysiology of schizophrenia.
- 12 March 2014
- Published by Georg Thieme Verlag KG in Klinische Neurophysiologie
- Vol. 45 (01) , P102
Impact of brain-derived neurotrophic factor (BDNF) gene polymorphism on cortical inhibition in schizophrenia
Introduction: Neuronal plasticity is a characteristic feature of the human central nervous system to dynamically respond to changes and demands inducing synaptical and neurochemical alterations. Using transcranial magnetic stimulation (TMS) in an intermittent theta-burst stimulation (iTBS) protocol, impaired cortical plasticity has been reported to be associated with a val/met gene-polymorphism in the brain-derived neurotrophic factor (BDNF) gene. Based on neuropathological findings and neuroimaging studies, impaired cortical plasticity has been described as a common, yet not fully understood phenomenon in patients with schizophrenia. Objectives: The aim of the present study was to investigate the impact of the val/met BDNF gene-polymorphism on cortical plasticity in patients with schizophrenia. Materials & Methods: Cortical plasticity was investigated using anodal and cathodal transcranial direct current stimulation (tDCS) applied to the primary motor cortex, thus inducing long-term potentiation (LTP) and long-term depression (LTD), respectively. LTP and LTD effects were probed by single and paired pulse TMS protocols before and after tDCS stimulation in a cross-sectional sample of schizophrenia patients (SZ) and healthy controls (HC). TMS in all participants was conducted using a standard 70 mm-TMS figure-of-eight magnetic coil connected to a MagPro X 100 magnetic stimulator. Analyses were focused on resting-motor threshold (RMT), 1mV motor-evoked potential (MEP), short-interval intracortical inhibition (SICI at 3 ms), intracortical facilitation (ICF at 12 ms) and cortical silent period (CSP at 120% RMT). Results: The statistical analyses included n = 43 SZ and n = 44 HC participants (all numbers presented under reserve of further examination) thus resulting in the largest available sample to probe cortical plasticity parameters in BDNF-genotyped schizophrenia patients. Further results will be presented at the conference. Conclusion: The findings will give new insights into the influence of plasticity-associated gene polymorphisms and the pathophysiology of schizophrenia.
- 28 September 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (11) , 1359-1368
Nationale und internationale Leitlinien zur Schizophrenie
- 28 September 2013
- Published by Springer Nature in Der Nervenarzt
- Vol. 84 (11) , 1359-1368
Nationale und internationale Leitlinien zur Schizophrenie